Carregando...
Ranolazine Induced Bradycardia, Renal Failure, and Hyperkalemia: A BRASH Syndrome Variant
Ranolazine is a well-known antianginal drug, that was first licensed for use in the United States in 2006. It was objectively shown to improve exercise capacity and to lengthen the time to symptom onset in patients with coronary artery disease. The most commonly reported side effects of ranolazine i...
Na minha lista:
| Publicado no: | Case Rep Med |
|---|---|
| Principais autores: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Hindawi
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6955118/ https://ncbi.nlm.nih.gov/pubmed/31975993 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2019/2740617 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|